The effects of dyslipidemia on the risk of type 2 diabetes (T2D) and related traits are not clear. We used regression models and 140 lipid-associated genetic variants to estimate associations between circulating HDL-cholesterol, LDL-cholesterol and triglycerides, and T2D and related traits. Each genetic test was corrected for effects of variants on the other two lipid types and surrogates of adiposity. We used the largest datasets available -34,840 T2D cases and 114,981 controls from the DIAGRAM consortium and up to 133,010 non-diabetic individuals for insulin secretion and sensitivity, from the MAGIC and GENESIS studies.
Introduction
Type 2 diabetes is associated with dyslipidemia -higher circulating concentrations of triglycerides and small dense low-density lipoprotein cholesterol (LDL-C), and lower concentrations of high-density lipoprotein cholesterol (HDL-C) -but the causal relationship between dyslipidemia and type 2 diabetes has been difficult to disentangle (1) . The weight of evidence suggests that altered lipid concentrations are secondary to insulin resistance (2) or other factors associated with both lipids and diabetes (e.g. adiposity), but some studies suggest that dyslipidemia could contribute to the pathogenesis of type 2 diabetes (3) through mechanisms related to impaired protection of beta cells or endoplasmic reticulum stress (4) .
Recent studies of carriers of loss of function mutations in the ABCA1 gene provide evidence that altered cholesterol could affect insulin secretion in humans, although different studies have provided conflicting results (5; 6).
The relationship between lipid levels and diabetes is further complicated by the apparently causal link between statin therapy and increased risk of type 2 diabetes. Meta-analysis of randomized controlled trials and Mendelian randomization analysis (7) provide evidence that statin treatment results in a slightly increased risk of diabetes. The Mendelian randomization study showed that a common allele in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene (encoding the target of statins) associated with lower LDL-C was also associated with higher risk of diabetes and that this risk was potentially mediated through a slight increase in BMI. The mechanism by which statins could increase risk of diabetes is not known but other theories include direct effects of statins on insulin secretion, reduced translocation of GLUT-4 to membranes in target tissues and reduced intracellular signaling (7; 8) .
Several studies have used a Mendelian randomization approach trying to assess the causal relationship between circulating lipids and type 2 diabetes, but these studies have tended to include a relatively small number of studies and individuals, and have produced conflicting results. One study of 2,447 individuals with diabetes and 3,052 without diabetes found associations between genetically determined higher concentrations of triglycerides and lower concentrations of HDL-C and increased risk of type 2 diabetes (9) . A larger study of 5,637 diabetes cases and up to 8,271 non-diabetic individuals but using fewer genetic variants found no association between genetically determined higher concentrations of triglycerides and diabetes-related outcomes (10) .
Mendelian randomization studies usually require large sample sizes because genetic variants explain only a small fraction of the primary traits under investigation. In this study, we aimed to use genetic variants to investigate the relationships between circulating lipid fractions and type 2 diabetes by using all available data. This data included the latest GWAS meta-analyses of 34,840 type 2 diabetes cases and 114,981 controls (11) , and up to 133,010 individuals with intermediate trait measures (12; 13) . We assessed whether or not genetic variants associated with life-long differences in circulating triglyceride, HDL-C, and LDL-C levels were related to risk for type 2 diabetes and diabetes-related phenotypes including intravenous measurements of insulin sensitivity. In this context, we also discuss the limitations of the Mendelian randomization approach when using SNPs that could be associated with multiple metabolic traits.
Methods

Genetic instruments
To create genetic instruments, we selected 185 independent (linkage disequilibrium r 2 <0.05) single nucleotide polymorphisms (SNPs) from 157 loci associated with triglycerides, HDL-C and/or LDL-C in the most recent meta-analysis of circulating lipid concentrations including 188,577 participants (14) . We started from the 185 SNPs as in the publication by Do et al., who assessed the association between genetically determined lipid concentrations and coronary heart disease (15).
We excluded those SNPs associated at p<10 -4 with the major confounding phenotypes, BMI
and WHRadjBMI (as such SNPs could be assumed to be primarily associated with these phenotypes), or that were associated with the outcomes (T2D or glycemic traits) with effect sizes of more than 2 SDs greater than the average lipid SNP (as such SNPs could be assumed to be primarily associated with the outcome, rather than lipid levels; 
The association of lipid-associated SNPs with lipid traits
We used the effect sizes of each SNP on triglycerides, HDL-C and LDL-C from published data (14; 15) , where the per-allele effects on each lipid trait were reported in SD-units based on inverse normal-transformed residuals of lipid concentrations after adjustment for age and sex. For the largest cohort, deCODE (n=15,612), the reported SD units per lipid trait were: HDL-C, 17.9 mg/dl; LDL-C, 39.9 mg/dl and triglycerides, 81.8 mg/dl.
The association of lipid-associated SNPs with diabetes and diabetes-related traits
The effect estimates of each lipid SNP on type 2 diabetes and diabetes-related traits were obtained from genome-wide association study (GWAS) meta-analysis results using the largest study sizes available. 
Statistical analysis
Primary analysis
For the analysis of the genetic association between circulating lipids and type 2 diabetes and diabetes-related traits, we used the framework proposed by Do et 
Subset of lipid SNPs excluding those with disproportionately large contributions
We also evaluated whether single SNPs with high influence on the primary analysis models as estimated by `difference in fits' (DFITS) as defined by Belsley et al., (18) were critical for the model results by rerunning the models without SNPs with absolute DFITS>0.4 (2√((k+1)/(nk-1)), where k is the number of predictors and n is the number of observations (here SNPs) (18) . However, even with this approach, we note that we cannot account for all sources of pleiotropy for reasons we expand on in the discussion.
Subsets of SNPs with more lipid-specific associations
In sensitivity analyses, we constructed genetic risk scores for individual lipid fractions based Table 2 ). These more specific risk scores explained 0.2, 0.9 and 1.0% of the variance in their respective lipid levels while the 140 SNP scores explained 3.7, 5.8, and 6.6 % for triglycerides, HDL-C and LDL-C, respectively. Due to the small number of genetic variants and amount of phenotypic variance explained by the five triglyceride SNPs we did not pursue this analysis any further. We then assessed the association of these scores with type 2 diabetes and diabetes-related traits on summary level data using the method described by Dastani et al. (19) , implemented in the R-package "gtx". Briefly, the effect of each of the three lipid scores on diabetes and related traits was calculated as ∑ ‫ݓ‬ ߚ ‫ݏ‬
where β i is the effect of the lipid-increasing alleles on diabetes, s i its corresponding standard error and w i the SNP effect on the respective lipid. We used the formula 2pq*beta 2 to estimate the variance explained by the different scores, where p and q are the allele frequencies for the major and minor alleles and beta is the estimated effect size.
Subsets of lipid SNPs identified through clustering methods
We used hierarchical clustering analysis to group 140 SNPs based on their effect on HDL-C, LDL-C and triglycerides. We used "Euclidean" metrics to calculate pairwise distance between the effect sizes on lipid levels of the 140 SNPs as input data and used "Ward" as a cluster method in the gplots package in R (Supplementary Figure 2) . This method has been used before to cluster fasting insulin associated genetic variants using metabolic traits (20) . We then assessed the impact of each cluster on T2D and related outcomes, using genetic risk scores weighted on each SNP's effect on dyslipidemia ((LDL-C+triglycerides-HDL-C)/3) and calculations using the method described by Dastani et al. (19) (see Subsets of more lipidspecific SNPs above).
Results
Associations between genetically determined high-density-lipoprotein cholesterol levels and diabetes traits
Primary analysis
We did not identify consistent associations between genetically higher circulating HDL-C and risk of type 2 diabetes, as assessed by our 140 SNP risk score using HDL-C effect sizes for each SNP (β [HDL-C] versus β diabetes ). In an unadjusted model, we observed a borderline association between genetically higher HDL-C and lower risk of type 2 diabetes (β=-0.15,
P=2x10
-3 ), but this association was attenuated after adjusting for the effects on other lipids and surrogates of adiposity (β=-0.12, P=0.03) ( Table 1 ). Note that the coefficients can be interpreted as the estimated causal effect associated with one SD-unit increase in HDL-C.
Hence, we estimated that one SD-unit increase of HDL-C was associated with an 11%
reduction of relative risk of diabetes (OR=e -0.12 =0.89).
We did not identify consistent associations between genetically higher circulating HDL-C (β HDL-C ) and intermediate measures of glycemia in non-diabetic individuals. The HDL-C (β HDL-C ) risk score was associated with lower fasting glucose (β glucose ) in unadjusted models (β=-0.04, P=4x10 -5 ) but this association was attenuated when adjusting for the effects of SNPs on the other two lipid types and surrogates of adiposity (β=-0.03, P=3x10 -3 ). There was no association with glucose stimulated measures of insulin secretion (disposition index). There were no associations between genetically higher circulating HDL-C and measures of insulin sensitivity as measured using an OGTT, or using intravenous measurements or fasting insulin in the adjusted models.
Subsets of lipid SNPs excluding those with disproportionately large contributions
We evaluated the impact of removing single influential SNPs by rerunning the fully adjusted models excluding the 8-13 SNPs with absolute DFITS>0.4. We found similar beta estimates, but the estimates for type 2 diabetes and fasting glucose no longer reached the Bonferronicorrected level of significance. In this analysis, we found a positive association between HDL-C (as assessed by genetic variants) and insulin sensitivity as measured using an OGTT (Table 2) .
Subsets of SNPs with more lipid-specific associations
The nominal association between genetically higher circulating HDL-C and lower risk of type 2 diabetes was consistent in a sensitivity analysis including 23 SNPs with disproportionately strong associations with HDL-C compared to triglycerides and LDL-C, although the strength of significance was reduced (β=-0.19, P=0.04). We also observed an association between higher HDL-C genetic risk score and lower disposition index (lower insulin secretion), which was not observed in the main analysis of 140 SNPs but this result is inconsistent with the HDL-C risk score -T2D association. There was no evidence of association between genetically higher circulating HDL-C and any other glycemic measures in the sensitivity analyses. The results from these analyses are presented in Table 3 .
Subsets of lipid SNPs identified through clustering methods
We next analyzed a genetic risk score consisting of SNPs that clustered together as a group where HDL-C lowering alleles tended to associate with neutral or positive effects on LDL-C and triglycerides (black cluster in Supplementary Figure 2) . Results from this set of SNPs were consistent with the main and other secondary analysis: the group of SNPs where alleles were associated with lower HDL-C concentrations was associated with increased risk of T2D, raised fasting glucose and lower insulin sensitivity (Supplementary Table 3 ).
Associations between genetically determined low-density-lipoprotein cholesterol levels and diabetes traits
Primary analysis
We identified an association between genetically higher circulating LDL-C and lower risk of type 2 diabetes, as assessed by our 140 SNP risk score using LDL-C effect sizes for each SNP (β LDL-C versus β diabetes ) in the unadjusted model (β=-0.14, P=1x10
) and even more strongly after adjusting for effects on other lipids and surrogates of adiposity (β=-0.21, P=5 x10 -6 ) ( Table 1) . We did not identify any consistent associations between genetically higher circulating LDL-C (β LDL-C ) and intermediate glycemic traits, although there was a nominal association with lower fasting glucose in non-diabetic individuals (β glucose versus β diabetes, β=-0.02, P=0.01) in models adjusted for the other two lipid fractions and surrogates of adiposity.
There were no associations with measures of stimulated insulin secretion or insulin sensitivity in the analyses.
Subsets of lipid SNPs excluding those with disproportionately large contributions
We evaluated the impact of removing single influential SNPs by rerunning the fully adjusted models excluding the 8-13 SNPs with absolute DFITS>0.4. We found similar results in this analysis as in the primary analysis ( Table 2) .
Subsets of SNPs with more lipid-specific associations
The strength of the association of LDL-C and T2D was dramatically smaller (and statistically non-significant) in a sensitivity analysis including 26 SNPs with disproportionately strong associations with LDL-C compared to triglycerides and HDL-C. There were no associations with measures of stimulated insulin secretion or insulin sensitivity in the analyses ( Table 3) .
Subsets of lipid SNPs identified through clustering methods
We next analyzed a genetic risk score consisting of SNPs that clustered together as a group
where LDL-C raising alleles tended to associate with weak positive effects on triglycerides and largely neutral effects on HDL-C (red cluster in Supplementary Figure 2) . Results from this set of SNPs were consistent with other results: the group of SNPs where alleles associated with higher LDL-C was associated with a lower risk of T2D (Supplementary Table 3 ). A third cluster of SNPs contained weakly LDL-C lowering or neutral alleles and these alleles tended to have neutral effects on HDL-C and weak negative or neutral effects on triglycerides. This cluster of SNPs was not associated with any diabetes related traits.
(Supplementary Table 3 , green cluster in Supplementary Figure 2) .
Associations between genetically determined triglyceride levels and diabetes traits
Primary analysis
We did not identify any consistent associations between genetically higher circulating triglycerides and higher risk of type 2 diabetes, as assessed by our 140 SNP risk score using triglyceride effect sizes for each SNP (β triglycerides versus β diabetes ). We observed only very slight trends of association between genetically higher circulating triglycerides and higher risk of type 2 diabetes (β=0.13, P = 0.04), and higher fasting glucose (β glucose (β =0.02, P=0.04)) and insulin (β insulin (β =0.03, P=0.03)) in non-diabetic individuals in adjusted models. There were no associations with measures of stimulated insulin secretion or other measures of insulin sensitivity ( Table 1) .
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Subsets of lipid SNPs excluding those with disproportionately large contributions
We evaluated the impact of removing single influential SNPs by rerunning the fully adjusted models excluding the 8-13 SNPs with absolute DFITS>0.4. In this analysis, the trends of associations were abolished for type 2 diabetes and insulin (Table 2 ).
Discussion
Our study represents the most comprehensive genetic analysis of the role of the three main circulating lipid fractions in type 2 diabetes and related glycemic traits. We used results from the largest genome-wide association studies and 140 common genetic variants robustly associated with lipid fractions. In contrast, previous studies used a maximum of 5,637 type 2 diabetic cases and 67 SNPs (9; 10). Our results therefore add to the debate about the role of lipids in type 2 diabetes, but also highlight the complexities in using genetic risk scores and a Mendelian randomization approach to dissect directions of causality in complex metabolic traits and when there are potential pleiotropic effects or confounders.
Despite using data from the largest GWAS available, we did not identify consistent evidence for a causal role of circulating lipids in type 2 diabetes. Neither did we identify consistent evidence for a causal role of circulating lipids with high glucose levels, insulin secretion or insulin sensitivity measures in non-diabetic individuals.
We observed 8 of 21 association reaching a nominal P<0.05. The traits studied are correlated with each other, which could explain an inflation of low P-values. The associations were mainly observed for traits with large sample sizes (T2D, fasting insulin, fasting glucose), and we may not have had adequate statistical power for more specific measures of insulin secretion and sensitivity. However, even these eight associations that reached nominal significance either weakened when adjusting for the effects of the SNPs on other lipids (HDL-C), weakened in sensitivity analyses (LDL-C) or could be susceptible to unaccounted for confounding factors and biases (especially LDL-C).
We believe that the association between the HDL-C genetic risk score and T2D is worthy of follow-up. Our associations between HDL-C variants, and T2D and fasting glucose became weaker upon adjustment for other lipids and adiposity, but remained significant when analyzing a subset of SNPs with larger effects on HDL-C. Our HDL-C associations are also consistent with results from monogenic studies. There is prior genetic evidence for the causal role of HDL-C; the rare mutations in the ABCA1 gene that cause Tangier disease primarily cause low levels of circulating HDL-C and are associated with alterations in insulin secretion in humans (5; 6).
Our strongest association was that between genetically higher circulating LDL-C levels and lower risk of T2D. This association is consistent with the recent finding of Swerdlow et al. (7) that presented an association between the LDL-lowering allele in the HMGCR gene (encoding the target for statins) and increased risk of T2D. However, this association was attenuated in one of our sensitivity analyses. We did not include the HMGCR variant in any of our analyses because it is associated with BMI, and it may be that this association with adiposity may explain the differences between our results when using the more specific set of LDL-C variants and the results of Swerdlow et al.
In some cases, we observed a discrepancy between the main analysis and the secondary analysis, most notably for the LDL-C effect on T2D and glucose, as well as for the HDL-C effect on insulin secretion as measured by disposition index. These discrepancies maybe partly due to a relative lack of statistical power in the secondary analysis, but could also be due to bias by residual pleiotropic effects.
The LDL-C diabetes association may represent a genuine causal relationship, but also provides an opportunity to discuss some of the limitations of using SNPs affecting lipids in Mendelian randomization analyses. There are several ways in which associations between lipid SNPs and diabetes could be confounded or biased. First, carrying a larger number of LDL-C raising alleles will increase the chances of a person requiring statin therapy. Because statin therapy appears to causally increase the risk of type 2 diabetes this could result in a non-causal association between genetically higher LDL-C and increased risk of diabetes.
However, we saw the opposite association, suggesting such confounding was not the explanation of our findings. Second, carrying a larger number of LDL-C raising alleles may have increased a type 2 diabetic patient's chances of dying from a heart attack, or being too ill to participate in a study, relative to a non-diabetic patient's survival chances. This survival bias could result in a non-causal association between genetically higher LDL-C and reduced risk of diabetes because diabetic cases in a study may be depleted of LDL-C raising alleles.
This survival bias could explain our association. Future studies using longitudinal cohorts may help solve this issue. Third, it is possible that the LDL-C effect of any lipid SNP on diabetes-related outcomes is underestimated because an LDL-C raising SNP is more likely to result in statin therapy, which will lower LDL-C effects. Fourth, it is extremely difficult to account for pleiotropic effects. We used several approaches to minimize the influence of pleiotropy but it is unlikely that we accounted fully for its effects and when we did use a more LDL-cholesterol specific set of SNPs the associations with diabetes were attenuated. We had to exclude 24% of SNPs (45/185) with known likely pleiotropic effects, which raises the likelihood that other SNPs have unknown pleiotropic effects. Whilst we accounted for other lipids and surrogate measures of adiposity including BMI and waist-hip ratio, we did not account fully for SNPs that may have primary effects on insulin resistance because insulin resistance is one of the main traits on a potential causal pathway (12; 20) . These issues have been discussed in a recent paper by Burgess et al, who proposed to re-assess models excluding SNPs with disproportionate effects on outcome compared to their effects on lipids (21) . We did exclude SNPs with disproportionately large effects on diabetes-related outcomes, but SNPs primarily associated with insulin sensitivity-related may remain in the analysis. Including only SNPs where the exact causal gene and role in lipid metabolism is not currently feasible, because too little is currently known about the exact mechanisms of most SNPs, and as a result, such analyses would be underpowered. Finally, another limitation is that we did not have information about the effect of the included SNPs on more specific lipid moieties and fractions, such as different free fatty acids, and we cannot exclude that the investigated SNPs have a primary effect on these moieties rather than the investigated lipid fractions.
Conclusion
We used the largest datasets available -140 lipid SNPs, 34,840 diabetes cases and up to 133,010 non-diabetic individuals -and found some evidence of an inverse association of both genetically determined HDL-C and LDL-C with type 2 diabetes. However, as discussed in detail, these associations could be caused by survival bias, pleiotropy or unknown confounding factors and should be interpreted with caution. Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; β (95% CI), beta coefficient with a 95% confidence interval for correlation of β lipid with β outcome ; OGTT, oral glucose tolerance test.
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